See more : Multikarya Asia Pasifik Raya Tb (MKAP.JK) Income Statement Analysis – Financial Results
Complete financial analysis of Allena Pharmaceuticals, Inc. (ALNAQ) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Allena Pharmaceuticals, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- ION Acquisition Corp 3 Ltd. (IACC) Income Statement Analysis – Financial Results
- Chenzhou City Jingui Silver Industry Co., Ltd. (002716.SZ) Income Statement Analysis – Financial Results
- Trustcash Holdings, Inc. (TCHH) Income Statement Analysis – Financial Results
- ServisFirst Bancshares, Inc. (SFBS) Income Statement Analysis – Financial Results
- GreenVision Acquisition Corp. (GRNVR) Income Statement Analysis – Financial Results
Allena Pharmaceuticals, Inc. (ALNAQ)
About Allena Pharmaceuticals, Inc.
Allena Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes oral enzyme therapeutics to treat patients with rare and severe metabolic, and kidney disorders in the United States. Its lead product candidate is ALLN-346, a novel and urate degrading enzyme for patients with hyperuricemia and gout in the setting of advanced chronic kidney disease. The company was incorporated in 2011 and is headquartered in Newton, Massachusetts. On September 2, 2022, Allena Pharmaceuticals, Inc., filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.
| Metric | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 20.38M | 20.38M | 37.24M | 26.38M | 15.52M | 20.10M | 11.54M |
| General & Administrative | 11.60M | 11.60M | 9.68M | 8.64M | 5.43M | 4.08M | 2.37M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 576.00K | 0.00 | 0.00 | 0.00 |
| SG&A | 11.60M | 11.60M | 9.68M | 9.22M | 5.43M | 4.08M | 2.37M |
| Other Expenses | 0.00 | 0.00 | 605.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 31.99M | 31.99M | 46.92M | 35.59M | 20.95M | 24.19M | 13.91M |
| Cost & Expenses | 31.99M | 31.99M | 46.92M | 35.59M | 20.95M | 24.19M | 13.91M |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 510.00K | -510.00K | 270.00K | 575.00K | -443.00K | 0.00 | 0.00 |
| Depreciation & Amortization | 363.00K | 166.00K | 163.00K | 78.00K | 73.00K | 46.00K | 98.00K |
| EBITDA | -31.97M | -32.68M | -47.18M | -35.57M | -21.58M | -24.46M | -14.15M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -32.34M | -31.99M | -46.92M | -35.59M | -20.95M | -24.19M | -13.91M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -510.00K | -859.00K | 0.00 | -55.00K | -700.00K | -321.00K | -342.00K |
| Income Before Tax | -32.85M | -32.85M | -47.34M | -35.65M | -21.65M | -24.51M | -14.25M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 510.00K | -859.00K | -419.00K | -55.00K | -700.00K | -321.00K | -342.00K |
| Net Income | -33.36M | -32.85M | -47.34M | -35.65M | -21.65M | -24.51M | -14.25M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -1.03 | -1.01 | -2.13 | -1.72 | -4.79 | -1.60 | -0.93 |
| EPS Diluted | -1.03 | -1.01 | -2.13 | -1.72 | -4.79 | -1.60 | -0.93 |
| Weighted Avg Shares Out | 32.51M | 32.51M | 22.18M | 20.74M | 4.52M | 15.28M | 15.29M |
| Weighted Avg Shares Out (Dil) | 32.51M | 32.51M | 22.18M | 20.74M | 4.52M | 15.28M | 15.29M |
Source: https://incomestatements.info
Category: Stock Reports